Egetis Therapeutics: Additional comment on financing - Redeye

Redeye provides an additional comment on the news that Egetis Therapeutics has secured in total SEK462m in funding, including SEK172m from a directed issue/private placement. We see this as a significant de-risk and argue that the positive reaction in the share price is warranted given the low expectations baked into today’s valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/946480/egetis-therapeutics-additional-comment-on-financing?utm_source=finwire&utm_medium=RSS